Abstract
The objective of this study was to describe a pilot trial of using an omega-3 fatty acid (docosahexaenoic acid [DHA]) to prevent islet cell autoimmunity in infants with an increased risk for developing type 1 diabetes (T1D). Infants from pregnant mothers who either have T1D (or the father or a previous child has T1D) and who entered the study in the third trimester or infants younger than age 5 months having a first-degree family member with T1D were eligible for the study. Infants from either group also had to have an increased genetic (HLA) risk for T1D (or multiple first-degree relatives with T1D) to be eligible. The study is a multicenter, 2-arm, randomized, double-masked clinical trial that will last 4 years (1 year of recruitment and 3 years of treatment). Treatment with DHA (or control) began in the last trimester of pregnancy or in the first 5 months after birth. Inflammatory mediators, including cytokines, chemokines, eicosanoids, and C-reactive protein, are being measured along with fatty acids in maternal and infant blood. Ninety-eight infants were enrolled (41 during pregnancy and 57 in the 5 months after birth). HLA results of the 97 eligible infants (1 infant had a protective 0602 allele and was thus ineligible) showed that 90 have DR3 and/or DR4. Seven infants were enrolled without DR3/4 but who instead had multiple first-degree relatives with T1D. Compliance has been excellent, and no families have discontinued participation. Intervention trials in this high-risk group are feasible but require significant effort to identify potential participants.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 98-107 |
| Number of pages | 10 |
| Journal | Infant, Child, and Adolescent Nutrition |
| Volume | 1 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2009 |
Fingerprint
Keywords
- chronic disease management
- diabetes (type 1 and 2)
- nutritional intervention
- prevent type 1
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Food Science
- Nutrition and Dietetics
Cite this
Nutritional Intervention to Prevent (NIP) Type 1 Diabetes A Pilot Trial. / Chase, H. Peter; Lescheck, Ellen; Rafkin, Lisa; Krause-Steinrauf, Heidi; Chritton, Sonia; Asare, Smita M.; Adams, Sara; Skyler, Jay S; Clare-Salzler, Michael.
In: Infant, Child, and Adolescent Nutrition, Vol. 1, No. 2, 2009, p. 98-107.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Nutritional Intervention to Prevent (NIP) Type 1 Diabetes A Pilot Trial
AU - Chase, H. Peter
AU - Lescheck, Ellen
AU - Rafkin, Lisa
AU - Krause-Steinrauf, Heidi
AU - Chritton, Sonia
AU - Asare, Smita M.
AU - Adams, Sara
AU - Skyler, Jay S
AU - Clare-Salzler, Michael
PY - 2009
Y1 - 2009
N2 - The objective of this study was to describe a pilot trial of using an omega-3 fatty acid (docosahexaenoic acid [DHA]) to prevent islet cell autoimmunity in infants with an increased risk for developing type 1 diabetes (T1D). Infants from pregnant mothers who either have T1D (or the father or a previous child has T1D) and who entered the study in the third trimester or infants younger than age 5 months having a first-degree family member with T1D were eligible for the study. Infants from either group also had to have an increased genetic (HLA) risk for T1D (or multiple first-degree relatives with T1D) to be eligible. The study is a multicenter, 2-arm, randomized, double-masked clinical trial that will last 4 years (1 year of recruitment and 3 years of treatment). Treatment with DHA (or control) began in the last trimester of pregnancy or in the first 5 months after birth. Inflammatory mediators, including cytokines, chemokines, eicosanoids, and C-reactive protein, are being measured along with fatty acids in maternal and infant blood. Ninety-eight infants were enrolled (41 during pregnancy and 57 in the 5 months after birth). HLA results of the 97 eligible infants (1 infant had a protective 0602 allele and was thus ineligible) showed that 90 have DR3 and/or DR4. Seven infants were enrolled without DR3/4 but who instead had multiple first-degree relatives with T1D. Compliance has been excellent, and no families have discontinued participation. Intervention trials in this high-risk group are feasible but require significant effort to identify potential participants.
AB - The objective of this study was to describe a pilot trial of using an omega-3 fatty acid (docosahexaenoic acid [DHA]) to prevent islet cell autoimmunity in infants with an increased risk for developing type 1 diabetes (T1D). Infants from pregnant mothers who either have T1D (or the father or a previous child has T1D) and who entered the study in the third trimester or infants younger than age 5 months having a first-degree family member with T1D were eligible for the study. Infants from either group also had to have an increased genetic (HLA) risk for T1D (or multiple first-degree relatives with T1D) to be eligible. The study is a multicenter, 2-arm, randomized, double-masked clinical trial that will last 4 years (1 year of recruitment and 3 years of treatment). Treatment with DHA (or control) began in the last trimester of pregnancy or in the first 5 months after birth. Inflammatory mediators, including cytokines, chemokines, eicosanoids, and C-reactive protein, are being measured along with fatty acids in maternal and infant blood. Ninety-eight infants were enrolled (41 during pregnancy and 57 in the 5 months after birth). HLA results of the 97 eligible infants (1 infant had a protective 0602 allele and was thus ineligible) showed that 90 have DR3 and/or DR4. Seven infants were enrolled without DR3/4 but who instead had multiple first-degree relatives with T1D. Compliance has been excellent, and no families have discontinued participation. Intervention trials in this high-risk group are feasible but require significant effort to identify potential participants.
KW - chronic disease management
KW - diabetes (type 1 and 2)
KW - nutritional intervention
KW - prevent type 1
UR - http://www.scopus.com/inward/record.url?scp=84998146100&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84998146100&partnerID=8YFLogxK
U2 - 10.1177/1941406409333466
DO - 10.1177/1941406409333466
M3 - Article
AN - SCOPUS:84998146100
VL - 1
SP - 98
EP - 107
JO - Infant, Child, and Adolescent Nutrition
JF - Infant, Child, and Adolescent Nutrition
SN - 1941-4064
IS - 2
ER -